BCR-ABL
-
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Congratulations! This is the latest cross-border licensing out deal by a pharma/biotech in China
-
总结 | 各类靶点的PROTAC专利布局概述
导读 今日分享葛兰素史克公司的 Andrew B Benowitz 等人发表在《Expert Opin Ther Pat》上的一篇总结性文章，该文对2013年…
